Dolby Laboratories Financial Statements (DLB)
|
|
|
|
Report date
|
|
|
17.11.2021 |
30.09.2022 |
18.11.2022 |
17.11.2023 |
19.11.2024 |
|
19.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 281 |
1 254 |
1 254 |
|
1 274 |
|
1 274 |
|
Operating Income, bln rub |
|
|
344.4 |
206.6 |
206.6 |
|
258.3 |
|
257.0 |
|
EBITDA, bln rub |
? |
|
464.1 |
320.9 |
329.9 |
|
258.3 |
|
342.3 |
|
Net profit, bln rub |
? |
|
310.2 |
184.1 |
184.1 |
|
360.6 |
|
261.8 |
|
|
OCF, bln rub |
? |
|
447.8 |
318.6 |
318.6 |
|
327.3 |
|
327.3 |
|
CAPEX, bln rub |
? |
|
54.5 |
47.9 |
59.5 |
|
30.0 |
|
30.0 |
|
FCF, bln rub |
? |
|
393.3 |
270.6 |
259.1 |
|
297.2 |
|
297.2 |
|
Dividend payout, bln rub
|
|
|
89.2 |
100.1 |
100.1 |
|
114.6 |
|
114.6 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
28.7% |
54.4% |
54.4% |
|
31.8% |
|
43.8% |
|
|
OPEX, bln rub |
|
|
810.5 |
905.8 |
895.2 |
|
868.5 |
|
876.2 |
|
Cost of production, bln rub |
|
|
130.0 |
141.4 |
141.4 |
|
140.5 |
|
140.5 |
|
R&D, bln rub |
|
|
253.6 |
261.2 |
261.2 |
|
263.7 |
|
263.7 |
|
Interest expenses, bln rub |
|
|
0.479 |
0.394 |
0.394 |
|
34.1 |
|
0.000 |
|
|
Assets, bln rub |
|
|
3 106 |
2 690 |
2 690 |
2 980 |
3 110 |
|
3 110 |
|
Net Assets, bln rub |
? |
|
2 598 |
2 246 |
2 246 |
2 355 |
2 477 |
|
2 477 |
|
Debt, bln rub |
|
|
72.1 |
50.9 |
50.9 |
50.6 |
47.0 |
|
47.0 |
|
Cash, bln rub |
|
|
1 264 |
809.3 |
809.3 |
884.5 |
482.0 |
|
577.8 |
|
Net debt, bln rub |
|
|
-1 192 |
-758.4 |
-758.4 |
-833.9 |
-435.1 |
|
-530.8 |
|
|
Ordinary share price, rub |
|
|
92.5 |
65.2 |
65.2 |
79.3 |
75.6 |
|
83.5 |
|
Number of ordinary shares, mln |
|
|
101.2 |
100.0 |
100.0 |
|
95.5 |
|
95.4 |
|
|
Market cap, bln rub |
|
|
9 357 |
6 514 |
6 514 |
0 |
7 224 |
|
7 961 |
|
EV, bln rub |
? |
|
8 165 |
5 756 |
5 756 |
-834 |
6 789 |
|
7 430 |
|
Book value, bln rub |
|
|
2 134 |
2 246 |
1 769 |
1 779 |
1 509 |
|
1 509 |
|
|
EPS, rub |
? |
|
3.07 |
1.84 |
1.84 |
|
3.77 |
|
2.74 |
|
FCF/share, rub |
|
|
3.89 |
2.71 |
2.59 |
|
3.11 |
|
3.12 |
|
BV/share, rub |
|
|
21.1 |
22.5 |
17.7 |
|
15.8 |
|
15.8 |
|
|
EBITDA margin, % |
? |
|
36.2% |
25.6% |
26.3% |
|
20.3% |
|
26.9% |
|
Net margin, % |
? |
|
24.2% |
14.7% |
14.7% |
|
28.3% |
|
20.6% |
|
FCF yield, % |
? |
|
4.20% |
4.15% |
3.98% |
0.00% |
4.11% |
|
3.73% |
|
ROE, % |
? |
|
11.9% |
8.20% |
8.20% |
0.00% |
14.6% |
|
10.6% |
|
ROA, % |
? |
|
9.99% |
6.84% |
6.84% |
0.00% |
11.6% |
|
8.42% |
|
|
P/E |
? |
|
30.2 |
35.4 |
35.4 |
|
20.0 |
|
30.4 |
|
P/FCF |
|
|
23.8 |
24.1 |
25.1 |
|
24.3 |
|
26.8 |
|
P/S |
? |
|
7.30 |
5.20 |
5.20 |
|
5.67 |
|
6.25 |
|
P/BV |
? |
|
4.38 |
2.90 |
3.68 |
0.00 |
4.79 |
|
5.27 |
|
EV/EBITDA |
? |
|
17.6 |
17.9 |
17.4 |
|
26.3 |
|
21.7 |
|
Debt/EBITDA |
|
|
-2.57 |
-2.36 |
-2.30 |
|
-1.68 |
|
-1.55 |
|
|
R&D/CAPEX, % |
|
|
465.8% |
544.9% |
439.3% |
|
878.7% |
|
878.7% |
|
|
CAPEX/Revenue, % |
|
|
4.25% |
3.82% |
4.74% |
|
2.36% |
|
2.36% |
|
| Dolby Laboratories shareholders |
